Literature DB >> 12620296

Inactivation of deoxycytidine kinase and overexpression of P-glycoprotein in AraC and daunorubicin double resistant leukemic cell lines.

Marjan J T Veuger1, M Willy Honders, Hananja E Spoelder, Roel Willemze, Renée M Y Barge.   

Abstract

AraC resistance in vitro is explained by inactivation of dCK, while resistance to DNR is described by overexpression of multidrug efflux pumps like Pgp or MRP. Thus far, no correlation between resistance mechanisms in vitro and in patients with AML has been documented. We generated AraC and DNR double resistant cell lines to investigate resistance mechanisms of both agents. In these cell lines involvement of dCK was extensively investigated and Pgp expression and activity was determined. Our data implicate that similar resistance mechanisms like inactivation of dCK coincided by alternatively spliced dCK forms and overexpression of Pgp are induced in single-as well as in double resistant leukemic cell lines.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12620296     DOI： 10.1016/s0145-2126(02)00224-2

Source DB:  PubMed          Journal:  Leuk Res        ISSN： 0145-2126            Impact factor:   3.156


  7 in total

Review 1.  The applications of the novel polymeric fluoropyrimidine F10 in cancer treatment: current evidence.

Authors:  William H Gmeiner; Waldemar Debinski; Carol Milligan; David Caudell; Timothy S Pardee
Journal:  Future Oncol       Date:  2016-06-09       Impact factor: 3.404

2.  Mechanisms of resistance to decitabine in the myelodysplastic syndrome.

Authors:  Taichun Qin; Ryan Castoro; Samih El Ahdab; Jaroslav Jelinek; Xiaodan Wang; Jiali Si; Jingmin Shu; Rong He; Nianxiang Zhang; Woonbok Chung; Hagop M Kantarjian; Jean-Pierre J Issa
Journal:  PLoS One       Date:  2011-08-17       Impact factor: 3.240

3.  Usefulness of PKH fluorescent labelling to study leukemic cell proliferation with various cytostatic drugs or acetyl tetrapeptide--AcSDKP.

Authors:  Jean Boutonnat; Anne-Marie Faussat; Jean-Pierre Marie; Jérôme Bignon; Johanna Wdzieczak-Bakala; Magali Barbier; Josiane Thierry; Xavier Ronot; Pierre-Emmanuel Colle
Journal:  BMC Cancer       Date:  2005-09-20       Impact factor: 4.430

4.  SLC29A1 single nucleotide polymorphisms as independent prognostic predictors for survival of patients with acute myeloid leukemia: an in vitro study.

Authors:  Haixia Wan; Jianyi Zhu; Fangyuan Chen; Fei Xiao; Honghui Huang; Xiaofeng Han; Lu Zhong; Hua Zhong; Lan Xu; Beiwen Ni; Jihua Zhong
Journal:  J Exp Clin Cancer Res       Date:  2014-11-15

Review 5.  Digging deep into "dirty" drugs - modulation of the methylation machinery.

Authors:  Lisa Pleyer; Richard Greil
Journal:  Drug Metab Rev       Date:  2015-01-08       Impact factor: 4.518

6.  Cytarabine-Resistant FLT3-ITD Leukemia Cells are Associated with TP53 Mutation and Multiple Pathway Alterations-Possible Therapeutic Efficacy of Cabozantinib.

Authors:  Ya-Chen Ko; Chung-Yi Hu; Zheng-Hau Liu; Hwei-Fang Tien; Da-Liang Ou; Hsiung-Fei Chien; Liang-In Lin
Journal:  Int J Mol Sci       Date:  2019-03-11       Impact factor: 5.923

7.  Expression of nucleoside-metabolizing enzymes in myelodysplastic syndromes and modulation of response to azacitidine.

Authors:  A Valencia; E Masala; A Rossi; A Martino; A Sanna; F Buchi; F Canzian; D Cilloni; V Gaidano; M T Voso; O Kosmider; M Fontenay; A Gozzini; A Bosi; V Santini
Journal:  Leukemia       Date:  2013-11-06       Impact factor: 11.528
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.